Skip to content

CJC-1295 / Ipamorelin

CJC ipaCJC-1295 with ipamorelinCJC/Ipa blend
PreclinicalProhibited in sport

Evidence

Preclinical

Typical vial

5 mg

Route

Subcut

Status

United States

What it is

The default growth hormone blend: a GHRH analogue with a ghrelin agonist, usually 5 mg of each. Two mechanisms that genuinely differ, unlike the triple.

Reviewed 25 Aug 2026

What is in the vial

The same name covers more than one vial. Pick the one you have — a dose in units written for one of these is wrong for the other.

10 mg vial — 5 mg of each
CompoundPer vialShareBought separately
CJC-1295GHRH analogue. Raises the size of the growth hormone pulse.5 mg50%$12–$36
IpamorelinGhrelin receptor agonist. Triggers a pulse without the appetite and cortisol effects of older secretagogues.5 mg50%$10–$27
Total10 mg$22–$64

The standard vial, and what most published protocols assume.

The ratio is fixed in the vial: choosing a dose of one component chooses the dose of all the others. The separate-vials column is the cheapest confirmed listing to the median across vendors, for the masses this vial holds. We do not price blend vials themselves — hold it against whatever you are being quoted.

The most widely sold blend in this category, and the one most protocols mean by 'the GH blend'. A 10 mg vial holds 5 mg of each; a 20 mg vial with 10 mg of each is also common.

The pairing has a clearer rationale than most blends. CJC-1295 is a GHRH analogue and ipamorelin acts at the ghrelin receptor, so they push growth hormone release through two different doors rather than competing at one. That is the argument for combining them, and it is a mechanistic argument rather than a studied one.

Almost always the no-DAC form of CJC-1295. The DAC version has a far longer half-life and a different dosing pattern, and a vial that does not say which one it contains cannot be dosed from a protocol that assumes either.

How it works

Two secretagogue mechanisms arriving together, not studied as a mixture.

CJC-1295 is a GHRH analogue: it acts at the GHRH receptor to increase the amplitude of a growth hormone pulse.

Ipamorelin is a selective ghrelin receptor agonist: it initiates a pulse, without the cortisol and prolactin rise older secretagogues produce.

Because the receptors differ, the stated rationale is additive release rather than one component crowding out the other.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

  • Raising growth hormone

    Published review

    What the blend is sold for.

    EvidenceBoth components raise GH separately in human studies. The mixture has not been studied.

Regulatory status

Last reviewed 25 Aug 2026. Positions in this category change frequently, so we date the line.

United States

Not approved anywhere as a mixture or as either of its parts. Sold as a research chemical, in at least two vial sizes at the same ratio.

Identity and clearance

What the molecule is, and how long a dose stays measurable.

Molecule

Class
Pre-mixed blend of two growth hormone secretagogues, 1:1 by mass

Usually CJC-1295 without DAC. The DAC form behaves differently enough that the two are not interchangeable.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Mixed sources

A week-by-week progression is also reported for CJC-1295 / Ipamorelin. See it against a 5 mg vial, where the syringe units can be worked out.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 5 mg vialSourceStart this protocol
Commonly described community protocol200 mcg – 300 mcgOnce daily before bed, 5 days a weekSubcutaneousTotal blend. At 1:1, 200 mcg of blend delivers 100 mcg of each component.12–18 uCommunity practiceStart this

The doses above in syringe units, for the vial you have:

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Work out what to draw

Pre-filled with a 10 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Tool
Dose unit
Your syringe
01020304050607080901004 units0.04 mL

Draw to 4 units on a 1 mL U-100 syringe. That is 0.04 mL, containing 200 mcg of CJC-1295 / Ipamorelin.

Concentration5mg / mL
Volume drawn0.04mL
Doses per vial50doses
Per unit50mcg / unit

4 units sits exactly on a printed line.

BioAlmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects, the situations that need care, and the ones that mean stop.

Read before dosing

Reported effects

  • Everything from two compounds at oncePublished review

    Unknown

    No human study of the mixture. Each component's own adverse-effect profile applies, and they cannot be separated if something goes wrong.

  • Injection site reactionsCommunity practice

    Commonly reported

  • Water retention, tingling or numbness in the handsCommunity practice

    Commonly reported

    Consistent with raised growth hormone generally rather than with this blend specifically.

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Persistent numbness or tingling in the hands, which can indicate fluid-related nerve compression.
  • New or worsening joint swelling.

Interactions and situations that need care

  • Active or previous cancerAvoid

    Raising growth hormone and IGF-1 is a proliferative signal, and neither component has been studied in anyone with a malignancy.

  • Diabetes or impaired glucose toleranceUse caution

    Growth hormone opposes insulin. Raising it can worsen glucose control.

  • Wanting to control the dose of one componentUse caution

    Two compounds at a fixed ratio means Two doses chosen at once. Running them separately is the only way to dose them separately.

  • Pregnancy and breastfeedingAvoid

    No safety data for any component, let alone the mixture.

  • Competing in a tested sportAvoid

    Components are WADA S2, prohibited at all times.

SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, at all times, in and out of competition. Growth hormone secretagogues are named explicitly in S2.

What to expect

What the sources describe over time, and how confident anyone can be about it.

No human efficacy data

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • The mixture has not been studied. Both components have separate human GH data.
  • The two mechanisms genuinely differ, which is more than can be said for the triple blend.
  • Sold at 5/5 and 10/10 under one name. Check which vial you have.
  • Almost always no-DAC CJC-1295. Confirm before using any protocol.

Storage and combinations

How to keep it, and what it does and does not go with.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

With other peptides

  • That blend contains both of these plus tesamorelin. Running both means taking CJC-1295 and ipamorelin twice.

  • Both contain ipamorelin and both raise growth hormone through a GHRH analogue. Running them together doubles the ipamorelin.

Check this against a whole stack

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it.

  • Clear and colourless after reconstitution

    Nothing here is coloured. A tinted solution is not this blend.

  • Cloudiness or visible particles

    Discard it.

  • No DAC status stated

    CJC-1295 with and without DAC are dosed differently. A vial that does not say cannot be dosed safely from either protocol.

Vocabulary on this page

Unit
A mark printed on an insulin syringe. A unit is not a fixed volume. What it represents depends entirely on the syringe's scale.
Secretagogue
A substance that makes the body release something it already produces, rather than supplying that thing from outside.
GHRH analogue
A synthetic version of the hormone that tells the pituitary to release growth hormone. One of the two receptor routes into a growth hormone pulse.
Blend
One vial containing several peptides at a fixed ratio, reconstituted and drawn together.
Half-life
The time it takes for half of a compound to be cleared from the body.
Vial
The small sealed glass container a peptide is sold in, holding a stated mass of freeze-dried powder under a rubber stopper.

The whole glossary →

Questions

Reader questions
Why combine a GHRH analogue with a ghrelin agonist?
They act at different receptors, so the stated rationale is that one raises the size of a pulse while the other triggers it. That is a mechanistic argument. No trial has tested whether the combination outperforms either alone.
DAC or no DAC?
Nearly always no DAC in these blends. The DAC form lasts days rather than minutes, so it is dosed weekly rather than daily — using a no-DAC protocol with a DAC vial, or the reverse, is not a small error.
Is 5/5 or 10/10 better?
They are the same ratio. The larger vial is more peptide per vial, not a stronger formulation, and a dose measured in units on one is wrong on the other.

References

Everything on this page that came from a source, with the source.

  1. Component evidence for common peptide blends: an assessment of what is known separately

    Preclinical peptide literature, 2024 · Assessment of the separate component literatures

    Cell culture and rodent models

    Every component of the common blends is supported by animal or cell-culture work only. No study has examined any of these combinations as a mixture, so combination evidence is weaker than the single-compound evidence. That is itself preclinical.

  2. Community and vendor practice, unverified

    Vendor listings and community protocols, 2026 · Anecdote

    Self-selected, unverified

    Ratios and doses as vendors sell and users describe them. Ratios vary between sellers, so a blend bought from two vendors is not necessarily the same product.

  3. Compiled community protocols

    BioAlmanac editorial summary of a public protocol compilation, 2026 · Not a study

    Records a week-by-week progression described on a vendor-adjacent protocol site, retrieved August 2026. Only the doses are taken from it. Its own syringe-unit conversions were checked against the vial sizes it states and several understate the volume by half, so nothing computed by that source is reproduced here — the units on this site are worked out from the vial in front of you. Carries no evidential weight about safety or effect.

CJC-1295 / Ipamorelin compared with

Also compared with GHK-Cu, Ipamorelin, CJC-1295, Tesamorelin, MK-677, GHRP-2.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. No clinician reviews these pages.

Page last updated 25 Aug 2026